Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Miers Laboratories Ltd.
WARNING LETTER
•Miers Laboratories Ltd.•May 21, 2025

Miers Laboratories Ltd. – FDA Warning Letter, May 21, 2025

Record Details

The FDA issued a Warning Letter to Miers Laboratories, Ltd following an inspection from May 19 to 21, 2025, for significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). Consequently, the company"s drug products are considered adulterated. Key issues identified included a critical failure to perform adequate identity testing on incoming drug components. Miers Laboratories relied solely on supplier certificates of analysis without proper validation, leading to the use of a solvent (propylene glycol) contaminated with unacceptable levels of ethylene glycol, a substance known for its lethal toxicity. The company also utilized homeopathic active ingredients that were over 14 years past their expiration without retesting. These component control deficiencies represent a repeat violation from a 2019 inspection. Furthermore, the quality control unit failed to provide sufficient oversight for manufacturing operations. This involved not maintaining appropriate batch production records and lacking established written procedures for managing quality functions like deviations and corrective actions, both of which are repeat violations from previous inspections (2014 and 2019). The FDA mandates a comprehensive review and remediation plan for the company"s material systems, including robust supplier qualification and incoming material testing, especially for potential contaminants like ethylene glycol in distributed products. A thorough assessment and enhancement of the Quality Control Unit"s authority, resources, and procedures are also required. Due to persistent repeat violations, the FDA strongly recommends engaging a qualified CGMP consultant to ensure compliance.

Company
Miers Laboratories Ltd.
Inspection date
May 21, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 1608761c-0925-4f7c-b28b-b9000d00f48a

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.2221 CFR 211.188(b)21 CFR 211.22(d)21 CFR 211.22(a)

Full citation text and observation details available on the Dashboard.

Other documents for Miers Laboratories Ltd.
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Miers Laboratories Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.